The World Health Organisation (WHO) has released the sum of one million dollars from the WHO Contingency Fund for Emergencies to support the scale-up of the Mpox response.
The Director-General, WHO Dr Tedros Ghebreyesus, said this on Wednesday during an online media conference.
Ghebreyesus said that the organisation planned to release more in the coming days.
According to him, the organisation has developed a regional response plan, requiring 15 million dollars to support surveillance, preparedness and response activities.
He said that two vaccines for Mpox have been approved by WHO-listed national regulatory authorities.
According to him, the vaccines are recommended by WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE).
“I have triggered the process for Emergency Use Listing of both vaccines, which will accelerate vaccine access particularly for lower-income countries, which have not yet issued their own national regulatory approval.
“Emergency Use Listing also enables partners including Gavi and UNICEF to procure vaccines for distribution,” he said.
The WHO boss said that since the beginning of 2024, the Democratic Republic of the Congo has been experiencing a severe outbreak of Mpox, with more than 14,000 reported cases and 511 deaths.
According to him, outbreaks of Mpox have been reported in DRC for decades, and the number of cases reported each year has been increasing steadily.
“However, the number of cases reported in the first six months in the year match the number reported in all of last year, and the virus has spread to previously unaffected provinces.
“In the past month, more than 50 confirmed and more suspected cases have been reported in four countries neighbouring the DRC that have not reported before: Burundi, Kenya, Rwanda and Uganda.
“Mpox outbreaks are caused by different viruses called clades,” he said.
Ghebreyesus said that Clade 1 has been circulating in the DRC for years, while Clade 2 was responsible for the global outbreak which began in 2022.
He said that the current outbreak in the Eastern DRC was caused by a new offshoot of clade 1, called clade 1b, which causes more severe disease than clade 2.
“Clade 1b has been confirmed in Kenya, Rwanda and Uganda, while the clade in Burundi is still being analysed.
“At the same time, cases of clade 1a have been reported this year in DRC, the Central African Republic and the Republic of Congo, while clade 2 has been reported in Cameroon, Côte d’Ivoire, Liberia, Nigeria and South Africa,” Ghebreyesus said.
According to him, WHO is working with the governments of the affected countries, the Africa CDC, NGOs, civil society and other partners to understand and address the drivers of these outbreaks.
“Stopping transmission will require a comprehensive response, with communities at the centre.
“WHO has Standing Recommendations on Mpox which include advice not to impose travel restrictions on affected countries,” he said.
Ghebreyesus said that WHO was grateful to Japan, the United States, the European Union and manufacturers for working with them on vaccine donations.
“We are working with all partners through the interim Medical Countermeasures Network to facilitate equitable access to vaccines, therapeutics, diagnostics and other tools.
“In light of the spread of Mpox outside DRC, and the potential for further international spread within and outside Africa, I have decided to convene an Emergency Committee under the International Health Regulations to advise me on whether the outbreak represents a public health emergency of international concern.
“The committee will meet as soon as possible and will be made up of independent experts from a range of relevant disciplines from around the world,” he said.
NAN
